Masonic Cancer Center, University of Minnesota

154 total trials 113 currently recruiting 29 completed

Trial Pipeline

RECRUITING NA

LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorectal Cancer

NCT07153016

RECRUITING Phase 2

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

NCT06792825

RECRUITING

UNTOLD Ovarian Cancer Unmet Needs Survey

NCT07070726

RECRUITING Phase 1

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

NCT07008638

RECRUITING NA

American Indian Smokefree Native RCT

NCT06544811

RECRUITING Phase 1

Trial of Cell Based Therapy for DMD

NCT06692426

RECRUITING

Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise

NCT05025774

RECRUITING Phase 1

Adenovirus (RGDCRAdCOX2F)

NCT06693986

RECRUITING Phase 2

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

NCT06377540

RECRUITING Phase 1

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

NCT06594445

RECRUITING Phase 2

Allo HSCT for High Risk Hemoglobinopathies

NCT06872333

RECRUITING NA

Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures

NCT06295757

RECRUITING Phase 1

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

NCT06342986

RECRUITING Phase 2

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

NCT06412497

RECRUITING

Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy

NCT06414278

RECRUITING Phase 2

Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy

NCT06411795

RECRUITING Phase 1

Study of PAT in Patients With Solid Tumor Cancers

NCT05338658

RECRUITING Phase 2

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

NCT05735717

RECRUITING Phase 2

Allo HSCT Using RIC and PTCy for Hematological Diseases

NCT05805605

RECRUITING Phase 2

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

NCT04105270

RECRUITING NA

Role of Acetaldehyde in the Development of Oral Cancer

NCT05973656

RECRUITING

Observational Study of Exposure to Environmental Toxicants Among Firefighters

NCT05643014

RECRUITING

Adrenoleukodystrophy National Registry Study

NCT03789721

RECRUITING Phase 2

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

NCT03579875

RECRUITING Phase 2

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NCT03314974

RECRUITING Phase 2

Auto Stem Cell Transplant for Lymphoma Patients

NCT03125642

RECRUITING NA

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

NCT01962636

RECRUITING Phase 2

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

NCT02605421

RECRUITING

Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation

NCT02161783

RECRUITING NA

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

NCT01666080

RECRUITING NA

Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

NCT01451502

ACTIVE NOT RECRUITING

Assessing the Time Demands of Cancer

NCT05708703

ACTIVE NOT RECRUITING NA

Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors

NCT05665543

ACTIVE NOT RECRUITING

Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.

NCT05634512

ACTIVE NOT RECRUITING Phase 1

NF-1, Nutraceutical Intervention

NCT05363267

ACTIVE NOT RECRUITING Phase 1

Biomarkers of Exposure and Effect in Standardized Research E-cigarette (SREC) Users

NCT04003805

ACTIVE NOT RECRUITING Phase 1

Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure

NCT03998735

ACTIVE NOT RECRUITING Early Phase 1

Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel

NCT04514029

ACTIVE NOT RECRUITING Phase 2

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

NCT03934840

ACTIVE NOT RECRUITING Phase 2

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

NCT03674411

ACTIVE NOT RECRUITING Phase 2

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

NCT03642626

ACTIVE NOT RECRUITING Phase 2

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

NCT02171104

ACTIVE NOT RECRUITING NA

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

NCT01652092

COMPLETED NA

Feasibility Study - Filter Ventilation

NCT04514471

COMPLETED NA

EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity

NCT05809557

COMPLETED Phase 1

HCW9218 in Select Advanced Solid Tumors

NCT05322408

COMPLETED Early Phase 1

Impact of Low Nicotine Cigarette Messaging on Perceptions and Cigarette Choices

NCT04740008

COMPLETED Phase 1

FT516 and IL2 With Enoblituzumab for Ovarian Cancer

NCT04630769

COMPLETED Phase 2

Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens

NCT03978117

COMPLETED Phase 2

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

NCT04055844

COMPLETED Phase 2

Radiation and Combination Immunotherapy for Melanoma

NCT03850691

COMPLETED Phase 2

BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

NCT03294304

COMPLETED Phase 1

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

NCT03019666

COMPLETED Phase 1

HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma

NCT02370160

COMPLETED NA

Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

NCT02162420

COMPLETED Phase 2

NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases

NCT01370213

COMPLETED NA

Selecting a Favorable KIR Donor in Unrelated HCT for AML

NCT01288222

COMPLETED

Metabolism of NNK Among African Americans

NCT01158456

COMPLETED Phase 2

Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer

NCT01105650

COMPLETED Phase 1

Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer

NCT01009437

COMPLETED Phase 1

IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread

NCT01099631

COMPLETED Phase 1

Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

NCT01033552

COMPLETED

Iron Overload in Patients Undergoing Donor Stem Cell Transplant

NCT00888316

COMPLETED Phase 1

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

NCT00703638

COMPLETED Phase 1

Intrathecal Enzyme Replacement for Hurler Syndrome

NCT00638547

COMPLETED Phase 1

T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

NCT00602693

COMPLETED Phase 2

CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer

NCT00610740

COMPLETED Phase 2

Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia

NCT00274846

COMPLETED Phase 2

Stem Cell Transplant for Hemoglobinopathy

NCT00176852

COMPLETED Phase 2

Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

NCT00258427

COMPLETED Phase 2

Stem Cell Transplantation for Hurler

NCT00176917

COMPLETED Phase 2

Stem Cell Transplant for Inborn Errors of Metabolism

NCT00176904

What the Pipeline for Masonic Cancer Center, University of Minnesota Shows

According to the ClinicalTrials.gov registry, Masonic Cancer Center, University of Minnesota is linked to 154 US clinical trials across every stage of research activity. Of those, 113 studies are currently recruiting — about 73% of the sponsor's indexed portfolio — and 29 are already marked complete, representing roughly 19% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Masonic Cancer Center, University of Minnesota reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 76 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Masonic Cancer Center, University of Minnesota is Acute Myeloid Leukemia with 7 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial